J Cancer 2020; 11(7):1648-1656. doi:10.7150/jca.39319 This issue

Research Paper

Loss of SUSD2 expression correlates with poor prognosis in patients with surgically resected lung adenocarcinoma

Wei Guo1#, Fei Shao3,1#, Sijin Sun1#, Peng Song1, Lei Guo2, Xuemin Xue2, Guochao Zhang1, Hao Zhang1, Yibo Gao1✉, Bin Qiu1, Fengwei Tan1, Shugeng Gao1✉, Jie He1✉

1. Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, The People's Republic of China
2. Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, The People's Republic of China
3. The Affiliated Hospital of Qingdao University and Qingdao Cancer Institute, Qingdao, Shandong 266071,The People's Republic of China
# Wei Guo, Fei Shao and Sijin Sun contributed equally to this study.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Guo W, Shao F, Sun S, Song P, Guo L, Xue X, Zhang G, Zhang H, Gao Y, Qiu B, Tan F, Gao S, He J. Loss of SUSD2 expression correlates with poor prognosis in patients with surgically resected lung adenocarcinoma. J Cancer 2020; 11(7):1648-1656. doi:10.7150/jca.39319. Available from https://www.jcancer.org/v11p1648.htm

File import instruction

Abstract

There is limited evidence regarding the relationship between the expression of Sushi Domain Containing 2 (SUSD2) and prognosis of patients with surgically resected lung adenocarcinoma (LUAD). This retrospective study aimed to investigate the clinical significance of SUSD2 expression in LUAD. To assess SUSD2 expression in LUAD, we conducted both integrated bioinformatic analysis based on the TCGA database and also immunohistochemistry study using a tissue microarray encompassing 578 LUAD cases from our hospital. Reduced SUSD2 expression was associated with gender, smoking history, higher pathological grade, lymph node metastasis, larger tumor length, advanced TNM stage. LUAD patients with SUSD2-positive tumors showed significantly better overall survival (OS) than those with SUSD2-negative tumors (P = 0.000). When patients were stratified into those with stage I (218, 37.7%), II (152, 26.3%) and III (208, 36.0%) disease, and those without (254, 43.9%) and with (324, 56.1%) lymph node metastasis, the prognostic effect was almost consistent. The OS of patients with positive SUSD2 expression was significantly better in patients with stage I (P = 0.000), III (P = 0.000), without (P = 0.000) and with (P = 0.001) lymph node metastasis. Multivariate analysis showed that loss of SUSD2 predicted a shorter survival time and was an independent prognostic factor for LUAD patients. Our study indicated that SUSD2 may serve as a new prognostic and potential therapeutic target in LUAD.

Keywords: Lung adenocarcinoma, Sushi Domain Containing 2, Prognosis, Immunohistochemistry, Biomarker